JP2024045113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024045113A5 JP2024045113A5 JP2023216987A JP2023216987A JP2024045113A5 JP 2024045113 A5 JP2024045113 A5 JP 2024045113A5 JP 2023216987 A JP2023216987 A JP 2023216987A JP 2023216987 A JP2023216987 A JP 2023216987A JP 2024045113 A5 JP2024045113 A5 JP 2024045113A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- crystal
- drug substance
- active ingredient
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210500296.8A CN114591304B (zh) | 2022-05-10 | 2022-05-10 | 一种化合物的结晶形式及其制备方法和用途 |
| CN202210500296.8 | 2022-05-10 | ||
| CN202210644417.6A CN114716417B (zh) | 2022-06-09 | 2022-06-09 | 化合物与富马酸的结晶形式的原料药及其药物组合物和用途 |
| CN202210644417.6 | 2022-06-09 | ||
| CN202211119888.1A CN115252619B (zh) | 2022-05-27 | 2022-09-15 | 药物组合物及其制备方法和用于治疗冠状病毒引起的疾病的用途 |
| CN202211119888.1 | 2022-09-15 | ||
| JP2022172288A JP7669325B2 (ja) | 2022-05-10 | 2022-10-27 | 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172288A Division JP7669325B2 (ja) | 2022-05-10 | 2022-10-27 | 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024045113A JP2024045113A (ja) | 2024-04-02 |
| JP2024045113A5 true JP2024045113A5 (enExample) | 2025-06-12 |
Family
ID=86385250
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172288A Active JP7669325B2 (ja) | 2022-05-10 | 2022-10-27 | 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 |
| JP2023216987A Pending JP2024045113A (ja) | 2022-05-10 | 2023-12-22 | 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 |
| JP2023216988A Pending JP2024056678A (ja) | 2022-05-10 | 2023-12-22 | 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172288A Active JP7669325B2 (ja) | 2022-05-10 | 2022-10-27 | 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216988A Pending JP2024056678A (ja) | 2022-05-10 | 2023-12-22 | 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US11655240B1 (enExample) |
| JP (3) | JP7669325B2 (enExample) |
| KR (1) | KR102533637B1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230302005A1 (en) * | 2022-03-25 | 2023-09-28 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Active pharmaceutical ingredient, preparation method thereof, and pharmaceutical composition including the same |
| US20230365536A1 (en) * | 2022-05-10 | 2023-11-16 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214242A (zh) | 2007-01-05 | 2008-07-09 | 上海艾力斯医药科技有限公司 | 新的药用组合物 |
| CA2687955C (en) | 2007-05-21 | 2015-06-30 | Toray Industries, Inc. | Crystalline micropowder particles |
| CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| CN101596189A (zh) | 2008-06-05 | 2009-12-09 | 上海艾力斯生物医药有限公司 | 含有咪唑-5-羧酸类衍生物的药用组合物 |
| RU2565073C2 (ru) * | 2010-08-10 | 2015-10-20 | Сионоги Энд Ко., Лтд. | Триазиновое производное и включающая его фармацевтическая композиция, обладающая анальгетической активностью |
| EP2468762A1 (en) * | 2010-11-30 | 2012-06-27 | Dr. Falk Pharma Gmbh | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size |
| US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN106994121B (zh) | 2016-01-26 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 一种用于治疗癌症的药物组合物 |
| JP6630229B2 (ja) | 2016-05-17 | 2020-01-15 | エルメッド株式会社 | レベチラセタム含有医薬組成物及びその製造方法 |
| WO2021183774A1 (en) | 2020-03-12 | 2021-09-16 | Angion Biomedica Corp. | Treating acute respiratory distress |
| CN113521289A (zh) | 2020-04-16 | 2021-10-22 | 中国科学院上海药物研究所 | 15种药物有效成分在抗病毒感染中的应用 |
| US20210346409A1 (en) | 2020-05-07 | 2021-11-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Covid-19 therapeutics and methods of treatment |
| CA3183740A1 (en) | 2020-06-10 | 2021-12-16 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| KR20210153908A (ko) * | 2020-06-11 | 2021-12-20 | 제이더블유중외제약 주식회사 | 코로나바이러스감염증-19(covid-19) 치료용 조성물 |
| KR20210158795A (ko) * | 2020-06-24 | 2021-12-31 | 뉴지랩파마 주식회사 | 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물 |
| WO2022035911A2 (en) | 2020-08-11 | 2022-02-17 | Tutela Pharmaceuticals, Inc. | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent |
| WO2022053993A2 (en) | 2020-09-12 | 2022-03-17 | Mylan Laboratories Limited | Treatments for sars-cov-2 infection (covid-19) |
| FI4122926T3 (fi) | 2021-04-14 | 2025-07-23 | Shionogi & Co | Triatsiinijohdannaisia, joilla on viruksien replikaatiota estävää aktiivisuutta, ja niitä käsittävä lääkekoostumus |
| CN113198019A (zh) | 2021-05-06 | 2021-08-03 | 叶绍朋 | 用于新冠状病毒肺炎感染初期治疗的药物组方 |
| JP7253866B1 (ja) | 2021-11-24 | 2023-04-07 | 塩野義製薬株式会社 | トリアジン誘導体を含有する経口投与する製剤 |
| CN114591304B (zh) | 2022-05-10 | 2022-07-12 | 北京远大九和药业有限公司 | 一种化合物的结晶形式及其制备方法和用途 |
| CN117159555A (zh) | 2022-05-27 | 2023-12-05 | 北京远大九和药业有限公司 | 药物组合物及其制备方法和用途 |
| CN117122601A (zh) | 2022-05-27 | 2023-11-28 | 北京远大九和药业有限公司 | 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途 |
| CN117247375A (zh) | 2022-06-09 | 2023-12-19 | 北京远大九和药业有限公司 | 化合物与富马酸的结晶形式的原料药及其药物组合物和用途 |
-
2022
- 2022-10-12 US US17/964,389 patent/US11655240B1/en active Active
- 2022-10-27 JP JP2022172288A patent/JP7669325B2/ja active Active
- 2022-11-07 KR KR1020220147414A patent/KR102533637B1/ko active Active
-
2023
- 2023-12-22 JP JP2023216987A patent/JP2024045113A/ja active Pending
- 2023-12-22 JP JP2023216988A patent/JP2024056678A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024045113A5 (enExample) | ||
| ES2617522T3 (es) | Procedimiento de granulación en seco para fabricar composiciones de comprimidos de metformina y composiciones de los mismos | |
| US20070036850A1 (en) | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound | |
| FI117373B (fi) | Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti | |
| JP2010535232A5 (enExample) | ||
| CN110944638A (zh) | 尼拉帕尼组合物 | |
| EA006386B1 (ru) | Фармацевтические композиции эстрогенных агентов | |
| EP2051694A2 (en) | Pharmaceutical compositions comprising aripiprazole | |
| US20250345323A1 (en) | LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS | |
| US20110196032A1 (en) | Pharmaceutical Dosage Form of an Antidepressant | |
| KR102022694B1 (ko) | 약학 조성물 | |
| WO2012055163A1 (zh) | 来曲唑i型结晶及其制备方法 | |
| CN101993417A (zh) | 磷酸二甲啡烷的稳定新晶型 | |
| JP2019194221A (ja) | 医薬製剤 | |
| GB2240472A (en) | Agent for use in the prevention, control or reversal of hypertension | |
| US12059419B2 (en) | Pharmaceutical composition comprising phthalazinone derivatives | |
| TWI730289B (zh) | 氨基吡喃衍生物的組合物 | |
| WO2013100870A1 (en) | New antipsychotic compositions | |
| TW200418486A (en) | Solid preparation | |
| WO2024232216A1 (ja) | テネリグリプチン含有製剤 | |
| JPWO2022031666A5 (enExample) | ||
| WO2024171708A1 (ja) | テネリグリプチン含有粒子及びそれを含む製剤 | |
| HK40029191A (en) | Composition of aminopyran derivative | |
| NZ776717B2 (en) | Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound | |
| JPWO2022143168A5 (enExample) |